Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference26 articles.
1. Khunti K. SGLT2 inhibitors in people with and without T2DM. Nat Rev Endocrinol. 2021;17(2):75–6.
2. Musso G, et al. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020;371: m4147.
3. US FDA. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious.
4. Health Products Regulatory Authority. SGLT2 inhibitors: updated advice on monitoring ketone bodies in patients hospitalised for major surgical procedures or acute serious medical illnesses. 2019. https://www.hpra.ie/docs/default-source/default-document-library/hpra-article-in-mims-supplement_november-2019.pdf.
5. Seki H, et al. Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol. BMJ Open. 2021;11(11): e049592.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献